Back to results
US 2024/0190936 A1Published application
Incretin Analogs and Uses Thereof
AssigneeEli Lilly and Company
InventorsJorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu
Life of this patent
Estimating the term…
Abstract
Incretin analogs are provided that have activity at each of the GIP. GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus. dyslipidemia. fatty liver disease, metabolic syndrome, non-alcoholic steato-hepatitis and obesity.
Claims25
An incretin analog comprising:
- YX2X3GTX6TSDYSIX13LDKX17AQX20AFIEYLLEGGPSSGAPPPS,
- wherein:
- X2 is Aib,
- X3 is Q or H,
- X6 is aMeF or αMeF(2F),
- X13 is L or aMeL,
- X17 is any amino acid with a functional group available for conjugation, and the functional group is conjugated to a C16-C22 fatty acid,
- X20 is Aib, Q or H,
- (SEQ ID NO:5), and the C-terminal amino acid is optionally amidated;
- or a pharmaceutically acceptable salt thereof.
7 more elements
(canceled)
An incretin analog having a formula selected from the group consisting of SEQ ID NOS:
- 5-7 and 9-11.
25-28. (canceled)
Dependencies are inferred from the claim text.